Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB CEO to Chair IMI Board for a Second Term

Published: Wednesday, April 02, 2014
Last Updated: Wednesday, April 02, 2014
Bookmark and Share
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.

UCB and IMI have announced that CEO Roch Doliveux has again been appointed Chair of the Governing Board of the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

UCB has been a member of IMI since its initiation in 2006 with Roch Doliveux joining the IMI Governing Board in May 2010, and Chairing the IMI Governing Board from 2012 to 2013.

IMI currently supports 46 projects with a combined budget of around €1.6 billion. IMI projects are tackling some of the biggest challenges in medicines research, with the goal speeding up the development of, and patient access to, better and safer medicines.

In addition, IMI supports a number of education & training projects. IMI has proved highly successful and a proposal to extend the initiative is now under discussion in the European Parliament and the EU Member States.

Roch Doliveux, CEO of UCB and Vice President of the European Federation of Pharmaceutical Association (EFPIA) says “Never has science given us so many opportunities to innovate and provide better health to citizens around the world. Yet science is now so complex that no one can harness its potential on its own. IMI is the biggest public-private partnership of its kind, and a role model for open innovation and knowledge sharing between the industry and academia. It is also without a doubt a key instrument to increase the well-being of patients across Europe.”

Michel Goldman, Executive Director of IMI said: “Roch Doliveux has long been a strong supporter of IMI, and his dedication and vision, and those of his colleagues on the Governing Board, have helped to make IMI the strong, successful organization it is today. I am confident that his leadership skills, combined with his focus on the needs of patients, will ensure IMI goes from strength to strength as it moves into the next phase of its existence.”

UCB is a significant contributor to the Innovative Medicines Initiative. UCB is participating in 21 of the consortia within IMI, leading 3 projects with academic partners: BTCURE, PRECISEADS and AETIONOMY.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Strategic collaboration commences with three discovery programs in areas of high patient need.
Friday, April 04, 2014
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!